###begin article-title 0
Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 222 226 222 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AIRE</italic>
###xml 116 123 <span type="species:ncbi:9606">patient</span>
###xml 517 525 <span type="species:ncbi:9606">patients</span>
###xml 739 746 <span type="species:ncbi:9606">patient</span>
Neutralizing autoantibodies to type I, but not type II, interferons (IFNs) are found at high titers in almost every patient with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), a disease caused by AIRE gene mutations that lead to defects in thymic T-cell selection. Combining genome-wide expression array with real time RT-PCR assays, we here demonstrate that antibodies against IFN-alpha cause highly significant down-regulation of interferon-stimulated gene expression in cells from APECED patients' blood by blocking their highly dilute endogenous IFNs. This down-regulation was lost progressively as these APECED cells matured in cultures without neutralizing autoantibodies. Most interestingly, a rare APECED patient with autoantibodies to IFN-omega but not IFN-alpha showed a marked increase in expression of the same interferon-stimulated genes. We also report unexpected increases in serum CXCL10 levels in APECED. Our results argue that the breakdown of tolerance to IFNs in AIRE deficiency is associated with impaired responses to them in thymus, and highlight APECED as another autoimmune disease with associated dysregulation of IFN activity.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 425 426 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 427 428 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 425 428 406 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup>
###xml 506 507 487 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 506 507 487 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B3">3</xref></sup>
###xml 629 630 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 631 632 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 629 632 599 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref></sup>
###xml 877 878 847 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 877 878 847 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B6">6</xref></sup>
###xml 1431 1432 1401 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1431 1432 1401 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B1">1</xref></sup>
###xml 1609 1610 1579 1580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 1611 1612 1581 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1613 1614 1583 1584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1614 1614 1584 1584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8"/>
###xml 1615 1616 1585 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1609 1616 1579 1586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref><xref ref-type="bibr" rid="B8"/>&#8211;<xref ref-type="bibr" rid="B9">9</xref></sup>
###xml 194 199 <span type="species:ncbi:9606">human</span>
###xml 1656 1664 <span type="species:ncbi:9606">patients</span>
Type I interferons (IFNs) are cytokines with pleiotropic activities that contribute to early defense against pathogens, development of adaptive immunity, and protective antitumor responses. The human type I IFN gene family consists of 13 distinct functional IFN-alpha, and single IFN-beta, IFN-Ïµ, IFN-kappa, and IFN-omega genes; the respective IFN molecules all use the same cell surface receptor complex, IFN-alpha receptor.1,2 Although seminal studies reported the expression of type I IFNs by monocytes,3 IFN-alpha, -beta, and -omega are secreted in much larger amounts by dendritic cells (DCs), above all by plasmacytoid DCs.4,5 However, virtually all nucleated cells can produce some type I IFNs after viral infection. The activation of IFN genes in DCs depends on IFN regulatory factors 7 (IRF7) and 3 (IRF3), the former termed "master regulator of type I IFN synthesis."6 After secretion and receptor binding, membrane-proximal immediate signaling is initiated through the catalytic activation of receptor-associated JAK1 and TYK2 tyrosine kinases. Transcription factors in the signal transducer and activator of transcription family members (STAT1 and STAT2) are then attached to the activated receptor complex via phosphotyrosine recruitment motifs and then undergo phosphorylation on tyrosine and, in complex with IRF9 protein, are translocated to the nucleus to up-regulate the expression of IFN-stimulated genes (ISGs).1 Type I IFNs are deeply implicated in pathogenesis of certain autoimmune diseases. In particular, in the chronic systemic autoimmune disease, systemic lupus erythematosus (SLE),2,5,7-9 IFN-alpha serum levels are elevated in patients with severe SLE and associated with the frequent up-regulation of ISGs, the so-called IFN signature in their peripheral blood mononuclear cells (PBMCs).
###end p 4
###begin p 5
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AIRE</italic>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 336 338 336 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B11">11</xref></sup>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 586 586 586 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12"/>
###xml 586 586 586 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13"/>
###xml 586 586 586 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14"/>
###xml 586 586 586 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15"/>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 584 589 584 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B11">11</xref><xref ref-type="bibr" rid="B12"/><xref ref-type="bibr" rid="B13"/><xref ref-type="bibr" rid="B14"/><xref ref-type="bibr" rid="B15"/>&#8211;<xref ref-type="bibr" rid="B16">16</xref></sup>
###xml 823 830 823 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Candida</italic>
###xml 997 999 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 997 999 997 999 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B17">17</xref></sup>
###xml 1093 1095 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1093 1095 1093 1095 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B18">18</xref></sup>
###xml 1185 1187 1177 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1188 1190 1180 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 1185 1190 1177 1182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B19">19</xref></sup>
###xml 1246 1250 1238 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aire</italic>
###xml 1356 1358 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1356 1358 1348 1350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B20">20</xref></sup>
###xml 1477 1479 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1477 1479 1469 1471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B21">21</xref></sup>
###xml 177 185 <span type="species:ncbi:9606">patients</span>
###xml 602 610 <span type="species:ncbi:9606">patients</span>
###xml 1058 1066 <span type="species:ncbi:9606">patients</span>
###xml 1261 1265 <span type="species:ncbi:10090">mice</span>
###xml 1414 1422 <span type="species:ncbi:9606">patients</span>
Recently, we reported high titer neutralizing autoantibodies to type I, but not type II, IFNs in autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED or APS1) patients,10 a recessive disorder resulting from mutations in the autoimmune regulator (AIRE) gene (7). Although AIRE has been detected in monocyte-derived DCs,11 the protein is principally expressed in medullary thymic epithelial cells (mTECs) where it is thought to control autoimmunity by regulating the expression of peripheral tissue-restricted antigens that induce self-tolerance in developing T cells.11-16 Most APECED patients develop multiple endocrine autoimmune diseases, often with high levels of serum autoantibodies against components of the affected organs. Highly variable clinically, APECED usually begins in infancy with chronic Candida infection, followed by autoimmune attack on the parathyroids, adrenal cortex, and/or gonads, endocrine cells in the gut, pancreatic islets, thyroid gland, and others.17 The prevalence of organ-specific autoantibodies in APECED patients varies between 8% and 66%.18 For those against IFN-omega or IFN-alpha, it reaches 100% or more than 95%, respectively.10,19 However, anti-IFN antibodies have not been reported in Aire-deficient mice, which do not precisely reproduce many characteristics of APECED, notably the candidiasis.20 Similar anti-IFN autoantibodies are also found in many patients with thymoma, especially those with myasthenia gravis.21
###end p 5
###begin p 6
###xml 257 265 <span type="species:ncbi:9606">patients</span>
Here we present new evidence supporting our hypothesis that, by specifically neutralizing IFN-alpha, these autoantibodies decrease expression of ISGs in APECED peripheral blood cells. The down-regulation of ISGs was not caused by any inherent defect in the patients' monocyte-derived DCs or plasmacytoid DCs, as it was reversible if they were cultured without neutralizing autoantibodies. We also report increase in serum chemokine (C-X-C motif) ligand 10 (CXCL10; alias IP-10) levels in APECED that most probably reflect increased production of proinflammatory cytokines in the target tissues.
###end p 6
###begin title 7
Methods
###end title 7
###begin title 8
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 8
###begin p 9
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AIRE</italic>
###xml 348 355 348 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 484 491 476 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 597 599 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 597 599 589 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 56 61 <span type="species:ncbi:9606">Human</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 498 505 <span type="species:ncbi:9606">patient</span>
###xml 535 542 <span type="species:ncbi:9606">patient</span>
###xml 612 620 <span type="species:ncbi:9606">patients</span>
###xml 873 880 <span type="species:ncbi:9606">patient</span>
With local approval from the Ethics Review Committee on Human Research of the University of Tartu, Estonia, and informed consent in accordance with the Declaration of Helsinki, we studied 8 APECED patients and age-matched controls. Their ages at sample collection, APECED features, and organ-specific autoantibodies and AIRE genotypes are given in Table 1. They all had high titers of neutralizing autoantibodies against IFN-omega, and the majority against the IFN-alpha in addition (Table 2), but patient A3 proved to be negative and patient A2 weakly positive in antiviral neutralization assays.10 None of the patients was taking systemic immunosuppressive treatment at the time of the sampling. Sera from Norwegian APECED and Addison disease collection, the Finnish APECED collection, a Sardinian APECED and unaffected heterozygous relative cohort, and some U.S. APECED patient sera and SLE sera from Tartu University Clinic serum bank were used for cytokine measurements.
###end p 9
###begin p 10
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AIRE</italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Disease characteristics, autoantibodies, and AIRE mutations of APECED patients of this study
###end p 10
###begin p 11
21OH indicates 21-hydroxylase; SCC, side-chain cleavage enzyme; AADC, aromatic L-amino acid decarboxylase; GAD, glutamic acid decarboxylase; TPH, tryptophan hydroxylase; 17OH, 17alpha-hydroxylase; A, adrenal insufficiency; HP, hypoparathyroidism; C, mucocutaneous candidiasis; G, primary gonadal insufficiency; V, vitiligo; Al, alopecia; AT, autoimmune thyroid disease; M, malabsorption; N, nail pitting; E, dental enamel hypoplasia; K, keratopathy; and D, type I diabetes.
###end p 11
###begin p 12
###xml 61 69 <span type="species:ncbi:9606">patients</span>
The titers of anti-IFN neutralizing autoantibodies in APECED patients of this study
###end p 12
###begin title 13
Cell isolation, dendritic cell generation, and cell stimulation
###end title 13
###begin p 14
###xml 826 827 826 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 873 874 873 874 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 946 950 <span type="species:ncbi:9913">calf</span>
PBMCs were separated from heparinized blood samples on Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, United Kingdom). The percentages of plasmacytoid DCs in PBMCs were determined using blood DC antigen 2 (BDCA2 or CD303) antibody and FACSCalibur (both BD Biosciences, San Jose, CA). The plasmacytoid DCs were obtained by positive sorting using anti-BDCA-4-conjugated magnetic microbeads (Miltenyi Biotec, Auburn, CA). The purity of the isolated cells was greater than 95% to 97%. Monocytes were isolated by positive sorting using anti-CD14-conjugated magnetic microbeads (Miltenyi Biotec) to purities greater than 99% and were cultured in 6-well tissue-culture plates with 50 ng/mL granulocyte-macrophage colony-stimulating factor and 25 ng/mL interleukin-4 (IL-4; both from R&D Systems, Minneapolis, MN) for 6 days at 106 cells/mL in RPMI 1640 supplemented with 2 mM l-glutamine, 100 U/mL penicillin, 100 mug/mL streptomycin, and 10% fetal calf serum (PAA Laboratories, Linz, Austria). By day 6, the monocyte-derived DCs stained negative with anti-CD14-allophycocyanin and positive with fluorescein isothiocyanate-anti-DC-specific intercellular adhesion molecule 3 grabbing nonintegrin (DC-SIGN; BD Biosciences). Plasmacytoid DCs were stimulated with Toll-like receptor 9 (TLR9) ligand CpG ODN (2.5 muM, M362; InvivoGen, San Diego, CA) or live influenza virus A/PR/8/34 (a gift from Dr Jim Robertson, National Institute for Biological Standards and Control) 1:100 for 6 hours. Monocyte-derived DCs were stimulated with Toll-like receptor 3 ligand polyinosinic:polycytidylic acid (25 mug/mL, poly(I:C); InvivoGen) for 18 hours.
###end p 14
###begin title 15
Affymetrix GeneChips
###end title 15
###begin p 16
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 483 485 483 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B22">22</xref></sup>
###xml 1436 1438 1435 1437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1436 1438 1435 1437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B23">23</xref></sup>
###xml 1544 1546 1543 1545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1544 1546 1543 1545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B24">24</xref></sup>
###xml 24 31 <span type="species:ncbi:9606">patient</span>
###xml 214 218 <span type="species:ncbi:9913">calf</span>
###xml 1090 1095 <span type="species:ncbi:9606">Human</span>
Buffy coats from APECED patient A8 with high-titer anti-type I IFN autoantibodies, and 2 healthy blood donors were cryopreserved in liquid nitrogen. Cells were thawed and cultured in RPMI 1640 containing 10% fetal calf serum for 72 hours. Monocyte isolation and DC differentiation were carried out as described in the previous section to yield "immature DCs." On day 7, some of the DCs were matured (mDCs) for 3 days with monocyte-conditioned medium prepared as previously described.22 RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA). RNA labeling and Affymetrix GeneChip hybridizations were done by the Australian Genome Research Facility. Briefly, 100 ng total RNA was amplified using T7-oligo dT and the Megascript T7 kit (Ambion, Austin, TX) following the Affymetrix manual (701725 rev5). A second round of cDNA synthesis was performed using some or all of the first round amplified RNA as indicated. Amplified RNA was biotin-labeled using the GeneChip IVT Labeling Kit; 15mug of labeled RNA was then fragmented as described in the Affymetrix manual (701725 rev5). The Human Genome U133 Plus 2.0 array slides arrays were hybridized overnight, washed as described in the Affymetrix manual (701725 rev5), and scanned using a GeneChip scanner 3000 (Affymetrix). For analysis of the Affymetrix GeneChips, the intensities for each probe set were normalized and summarized using the Robust Multi-array Analysis algorithm.23 Differential expression was assessed using empirical Bayes moderated t-statistics from the LIMMA package.24 Statistical analysis was performed by Ken Simpson. Further data analysis was performed using Microarray Data Analysis System, version 2.19 (MIDAS 2.19), and Multi Experiment Viewer, version 4.0 (MEV 4.0). The data obtained for the microarray analyses are deposited at  and can be accessed under "Gene expression profile of APCED monocytes and dendritic cells."
###end p 16
###begin title 17
Real-time RT-PCR
###end title 17
###begin p 18
###xml 662 663 662 663 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 882 883 882 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 895 896 887 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 896 897 888 889 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1000 1001 984 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 989 1001 981 985 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;&#916;<italic>C</italic></sup>
###xml 1001 1002 985 986 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sup>
###xml 1010 1011 994 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1011 1012 995 996 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1307 1312 1288 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Blood</italic>
RNA was extracted from the cell pellets using the RNeasy Micro Kit (QIAGEN, Hilden, Germany) with DNase treatment according to the manufacturer's instructions, or Trizol reagent (Invitrogen). Total RNA was reverse-transcribed to cDNA using SupersScript III (Invitrogen), 10 mM dNTP Mix, oligo(dT)18 primer, and RiboLock RNase inhibitor (Fermentas, Vilnius, Lithuania). The cDNA obtained was used for real-time quantitative polymerase chain reaction (RT-PCR) using ABI Prism 7900 sequence Detection System (Applied Biosystems, Foster City, CA) and qPCR SYBR Green Core Kit (Eurogentec, Seraing, Belgium) according to the manufacturer's instructions with 2 mM MgCl2. SYBR Green fluorescence was measured after each extension step, and the specificity of amplification was evaluated by melting curve analysis. The relative gene expression levels were calculated using the comparative Ct (DeltaDeltaCt) method (according to Applied Biosystems), where the relative expression is calculated as 2-DeltaDeltaCt, where Ct represents the threshold cycle. Every sample was run in 3 parallel reactions. Primers for all target genes and housekeeping beta-actin (ACTb) gene were designed to span exon boundaries in all multiexon genes with Primer Express (Applied Biosystems) and are listed in Table S1 (available on the Blood website; see the Supplemental Materials link at the top of the online article).
###end p 18
###begin title 19
Cytokine measurement
###end title 19
###begin p 20
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 136 143 <span type="species:ncbi:9606">patient</span>
###xml 162 167 <span type="species:ncbi:9606">Human</span>
###xml 386 393 <span type="species:ncbi:9606">patient</span>
IP-10 (CXCL10) Duo Elisa kit and Quantikine HS human IL-6 ELISA kit (both from R&D Systems) were used to detect their concentrations in patient and control sera. Human Th1/Th2 Cytokine Kit (Cytometric Bead Array, BD Biosciences) was used according to the manufacturer's instructions to measure IFN-gamma, tumor necrosis factor (TNF)-alpha, IL-10, IL-5, IL-4, and IL-2 concentrations in patient and control serum samples with the help of FACSCalibur.
###end p 20
###begin title 21
STAT1 phosphorylation
###end title 21
###begin p 22
###xml 224 225 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 465 466 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1189 1190 1168 1169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1196 1197 1175 1176 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sub>
###xml 1208 1209 1187 1188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1250 1251 1229 1230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sub>
###xml 7 12 <span type="species:ncbi:9606">human</span>
###xml 321 326 <span type="species:ncbi:9606">human</span>
Normal human PBMCs or U937 monocytic cell line were used. PBMCs were rested for 2 hours in the medium described in the second section and U937 cells were kept in serum-free medium for 12 hours. The cells were pelleted 2 x 105 per tube and resuspended in 100 muL of medium with the indicated concentrations of recombinant human IFN-alpha2 (PBL Biomedical Laboratories, Piscataway, NJ) and various concentrations of test sera. After 15 minutes at 37degreesC and 5% CO2, the cells were fixed immediately with an equal volume of Cytofix buffer and permeabilized in cold Perm Buffer III for 30 minutes on ice. The cells were stained with 5 muL anti-phospho-STAT1 (Y701)-Alexa Fluor 488 at room temperature for 1 hour, washed, and analyzed using FACSCalibur. The mean Alexa Fluor 488-fluorescence intensity (MFI) of the cells was analyzed using CELLQuest software (everything from BD Biosciences). To detect serum IFN-alpha activity, the cells were incubated in 50% serum for 15 minutes. In some tubes, blocking IFN-alpha antibody at 10 mug/mL (clone 9D3, Abcam, Cambridge, United Kingdom) or isotype control antibody (BD Biosciences) was added. Data were expressed as MFI units (MFI units = MFIt - MFIb) where MFIt represents value for test sample and MFIb value for background staining.
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Statistical analysis was done with the help of GraphPad Prism software (GraphPad Software, San Diego, CA). The mean values of different groups were compared using t test in the case of gene expression data and Mann-Whitney test in the case of cytokine concentrations. Bonferroni correction was used for multiple comparisons.
###end p 24
###begin title 25
Results
###end title 25
###begin title 26
Interferon-regulated gene expression is decreased in APECED blood cells
###end title 26
###begin p 27
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AIRE</italic>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 98 106 98 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B25">25</xref></sup>
###xml 797 799 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 800 802 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 797 802 786 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref></sup>
###xml 876 884 865 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 973 974 962 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1017 1018 1006 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1029 1033 1018 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;123</sup>
###xml 1035 1043 1024 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1186 1187 1175 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1198 1200 1187 1189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 1202 1210 1191 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1223 1224 1212 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1235 1237 1224 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 1239 1247 1228 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1267 1275 1256 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 343 348 <span type="species:ncbi:9606">Human</span>
High-titer anti-type I IFN autoantibodies are found in nearly 100% of AIRE-mutant APECED patients.10,19,25 They neutralize the antiviral actions of most type I IFNs, especially IFN-omega, but IFN-beta less frequently and the type II IFN-gamma almost never. To assess their potential effects on ISG expression patterns, we performed Affymetrix Human Genome U133 Plus 2.0 Array analyses on monocytes and monocyte-derived DCs. Readily isolated in large numbers from APECED and control subjects' blood, these cells are known type I IFN producers and responders. After normalization, the genes showing more than 1.5-fold changes in each of 2 experiments were considered to be differentially expressed. Using literature surveys, we selected a total of 285 genes (Table S2) that are up-regulated by IFNs.26,27 Strikingly, 61 of these genes were down-regulated for at least 1.5-fold (Figure 1A), and the number of down-regulated ISGs was highly significantly changed in APECED CD14+ monocytes compared with healthy controls (P = 3.9 x 10-123; Figure 1B). Notably, however, the differences (and their significances) waned as the monocytes matured in culture into immature dendritic cells (iDCs; P = 5.7 x 10-5; Figure 1B) and mDCs (P = 1.9 x 10-5; Figure 1B) as visualized in Figure 1A.
###end p 27
###begin p 28
###xml 0 76 0 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Microarray analysis of APECED and control monocytes and monocyte-derived DCs</bold>
###xml 683 684 681 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 716 717 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 147 154 <span type="species:ncbi:9606">patient</span>
###xml 359 366 <span type="species:ncbi:9606">patient</span>
Microarray analysis of APECED and control monocytes and monocyte-derived DCs. (A) The gene expression profiles (log2 of fold change between APECED patient A8 and control 2) of 61 differentially expressed ISGs in monocytes, iDCs, and mDCs. Most of the ISGs lost their differential expression by the iDC stage. (B) The differential expression of ISGs in APECED patient monocytes, iDCs, and mDCs. n indicates the total number of genes down-regulated 1.5-fold in each microarray data set. ISGs and non-ISGs indicate the number of genes, respectively, characterized or not characterized as ISGs. The expected numbers of ISGs and non-ISGs were calculated assuming the random selection. chi2 test was used to calculate the P values to determine whether the deviation is significant.
###end p 28
###begin p 29
###xml 498 506 490 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 666 673 654 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 675 683 663 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 418 426 <span type="species:ncbi:9606">patients</span>
###xml 589 596 <span type="species:ncbi:9606">patient</span>
###xml 654 661 <span type="species:ncbi:9606">patient</span>
###xml 700 707 <span type="species:ncbi:9606">patient</span>
###xml 810 818 <span type="species:ncbi:9606">patients</span>
To confirm this ISG down-regulation independently in more APECED patients, we next analyzed the expression of some well-known ISGs that showed reduced expression in our array experiments, using RT-PCR to quantitate transcripts in PBMCs freshly isolated ex vivo. The down-regulation clearly correlated with the presence of neutralizing autoantibodies specific for the IFN-alpha because it was evident in all the APECED patients with high titers of autoantibodies against several IFN-alpha subtypes (Figure 2A). In contrast, expression of ISGs was strongly increased in one Norwegian APECED patient with neutralizing autoantibodies against IFN-omega only (patient A3, Table 2; Figure 2A). Furthermore, patient A2 with low titers of anti-IFN-alpha antibodies showed the highest ISG expression levels among APECED patients with neutralizing autoantibodies against IFN-alpha for 7 of the 8 ISGs tested (data not shown).
###end p 29
###begin p 30
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Decreased expression of ISGs in APECED cell populations</bold>
###xml 162 163 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 191 192 187 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 623 624 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 634 635 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 647 648 639 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 677 678 669 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 209 217 <span type="species:ncbi:9606">patients</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
###xml 686 693 <span type="species:ncbi:9606">patient</span>
Decreased expression of ISGs in APECED cell populations. Expression of ISGs (A) and other genes (E) in freshly isolated PBMCs from IFN-alpha antibody-positive (Ab+, 4 cases) and -negative (Ab-, 1 case) APECED patients and healthy controls (Ctrl, 5 cases). (C) Expression of ISGs in freshly isolated plasmacytoid DCs (2 cases in each group). (B) Expression of ISGs in freshly isolated monocytes from IFN-alpha antibody-positive (6 cases) and -negative (1 case) APECED patients and healthy controls (7 cases). (D) Expression of ISGs in monocyte-derived DCs from APECED patients and healthy controls (3 cases in each group). *P < .05, **P < .001, ***P < .001, comparison of the Ab+ APECED patient and control blood cells. Bars represent group averages.
###end p 30
###begin p 31
###xml 182 190 182 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 345 354 345 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figures 1</xref>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 644 652 640 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 333 337 <span type="species:ncbi:9913">calf</span>
To identify the cell types affected, we then analyzed freshly isolated monocytes and plasmacytoid DCs. Notably, both cell types also showed similar down-regulation of the same ISGs (Figure 2B,C). Moreover, the down-regulated ISG pattern had normalized in monocyte-derived DCs that had differentiated for 6 days in culture with fetal calf serum (Figures 1A,B, 2D). In contrast with the ISGs, we saw no differences between the groups in the expression patterns of genes that are selectively (CIITA) or preferentially (CXCL9) regulated by IFN-gamma; nor for CCL5, a chemokine induced more by proinflammatory cytokines than type I IFNs, or IFNAR1 (Figure 2E).
###end p 31
###begin p 32
###xml 113 121 <span type="species:ncbi:9606">patients</span>
###xml 186 193 <span type="species:ncbi:9606">patient</span>
Taken together, these results show clearly decreased expression of all the classic ISGs tested in all the APECED patients with neutralizing antibodies against IFN-alpha, whereas, in one patient who has only anti-IFN-omega autoantibodies, it appeared to be strongly enhanced.
###end p 32
###begin title 33
APECED sera with anti-IFN-alpha inhibit ISG expression
###end title 33
###begin p 34
###xml 394 402 386 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 415 419 <span type="species:ncbi:9913">calf</span>
###xml 600 605 <span type="species:ncbi:9606">human</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
We next tested for acute effects of the neutralizing autoantibodies after incubating monocytes from healthy donors in medium containing 20% autologous plasma and 2% APECED or control sera for 18 hours. Expression of all the ISGs tested was significantly down-regulated by all the APECED sera that contained anti-IFN-alpha neutralizing autoantibodies, but not by the one specific for IFN-omega (Figure 3A). If fetal calf serum was used instead of autologous serum, no differences in ISG expression were seen in monocytes cultured in the presence of APECED or control sera (data not shown). Evidently, human plasma contains low levels of type I IFNs that can be blocked by the patients' neutralizing autoantibodies.
###end p 34
###begin p 35
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Effect of APECED sera on ISG expression and STAT1 phosphorylation</bold>
###xml 192 193 192 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 211 212 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 284 285 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 717 718 701 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 735 736 719 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 696 704 <span type="species:ncbi:9606">patients</span>
###xml 796 804 <span type="species:ncbi:9606">patients</span>
###xml 978 985 <span type="species:ncbi:9606">patient</span>
###xml 1037 1044 <span type="species:ncbi:9606">patient</span>
Effect of APECED sera on ISG expression and STAT1 phosphorylation. (A) Expression of ISGs in control monocytes incubated in 20% autologous sera with the addition of 2% APECED sera-positive (Ab+) or -negative (Ab-) for IFN-alpha antibodies, or with control serum (Ctrl) for 18 hours. *P < .05 between IFN-alpha antibody-positive APECED patients and healthy controls. (B) U937 cells were treated with 1000 U/mL IFN-alpha for 15 minutes or with the same concentration of IFN-alpha preincubated with 2%, 5%, or 10% of APECED (A1-A5) or 10% of control (C1-C3) sera, stained for intacellular pSTAT1 and measured by flow cytometry. (C) Control PBMCs were incubated with 50% of serum samples from APECED patients positive (Ab+) or negative (Ab-) for IFN-alpha antibodies, healthy controls (Ctrl), or SLE patients for 15 minutes and stained for intracellular pSTAT1 to test for IFN activity in the sera (left panel). Control PBMCs were incubated with 50% of serum samples from an APECED patient negative for IFN-alpha autoantibodies (A3), an SLE patient with IFN activity, or two healthy controls for 15 minutes with or without the addition of neutralizing anti-IFN-alpha antibody or isotype control antibody as indicated, and stained for intracellular pSTAT1 (right panel).
###end p 35
###begin p 36
###xml 427 435 415 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 622 630 602 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 510 517 <span type="species:ncbi:9606">patient</span>
To test whether these anti-IFN-alpha autoantibodies also inhibit IFN signaling, we assessed phosphorylation of STAT1 protein, a crucial early event after stimulation of the IFN receptor complex. Cells treated with IFN-alpha showed significant phosphorylation of STAT1 protein that was again inhibited, indeed, down to baseline levels, but only by APECED sera containing high titers of neutralizing autoantibodies to IFN-alpha (Figure 3B). By contrast, the IFN-omega-specific serum A3, and another from one SLE patient, induced STAT1 phosphorylation; that induction was specifically neutralized by anti-IFN-alpha antibody (Figure 3C). Together, the down-regulation of ISG expression and of STAT1 phosphorylation in the presence of APECED sera shows that the changes observed in the APECED cells are the result of autoantibody neutralization of IFN-alpha.
###end p 36
###begin title 37
###xml 7 15 <span type="species:ncbi:9606">patients</span>
APECED patients' plasmacytoid DCs and monocyte-derived DCs express normal levels of type I IFNs
###end title 37
###begin p 38
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 324 332 324 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
In response to viral stimulation, plasmacytoid DCs produce 10- to 100-fold more type I IFNs than monocytes. When PBMCs were stained for BDCA-2, a C-type lectin receptor that is specific for plasmacytoid DCs, their frequencies were slightly lower in APECED patients than in healthy controls, but not significantly (P = .079, Figure 4A).
###end p 38
###begin p 39
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Normal plasmacytoid DC numbers and dendritic cell IFN production in APECED</bold>
###xml 161 162 161 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 361 362 356 357 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 608 609 603 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 375 382 <span type="species:ncbi:9606">persons</span>
###xml 384 388 <span type="species:ncbi:9606">Ctrl</span>
###xml 596 604 <span type="species:ncbi:9606">patients</span>
###xml 633 637 <span type="species:ncbi:9606">Ctrl</span>
Normal plasmacytoid DC numbers and dendritic cell IFN production in APECED. (A) Percentages of plasmacytoid DCs (pDCs) among PBMCs in APECED and control groups (P = .079, t test). (B) Expression of type I IFN genes after plasmacytoid DC stimulation for 6 hours with live influenza virus (left panel) or 2.5 muM CpG (right panel) in IFN-alpha-positive APECED (Ab+) or control persons (Ctrl). (C) IRF3 and IRF7 expression in stimulated plasmacytoid DCs from APECED or control individuals. (D) Type I IFN gene expression was studied after 18 hours of stimulation of monocyte-derived DCs from APECED patients (Ab+) and healthy controls (Ctrl) with 25 mug/mL of poly(I:C).
###end p 39
###begin p 40
###xml 297 305 286 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 359 367 348 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 708 716 697 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
To assess the potential of these plasmacytoid DCs to autoimmunize against IFNs in APECED, we next measured their IRF and IFN expression after short-term stimulation with influenza virus or CpG. We found no significant differences in transcript levels of their IFN-alpha2, IFN-alpha8, or IFN-beta (Figure 4B) or of interferon-regulatory factors IRF3 and IRF7 (Figure 4C): indeed, the levels were even slightly lower in APECED than control plasmacytoid DCs. Because myeloid DCs also contribute significantly to the overall production of type I IFNs, we stimulated (precultured) monocyte-derived DCs for 18 hours with poly(I:C). Again, however, no differences were seen in expression of these type I IFN genes (Figure 3D).
###end p 40
###begin p 41
###xml 133 141 <span type="species:ncbi:9606">patients</span>
In conclusion, the numbers of plasmacytoid DCs and levels of type I IFN mRNA expression by dendritic cells were comparable in APECED patients and healthy controls, which argues against any inherent hyperactivation in circulating APECED DCs that could lead to the breakdown of tolerance to type I IFNs.
###end p 41
###begin title 42
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Elevation of serum CXCL10 levels in APECED patients
###end title 42
###begin p 43
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 128 128 128 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29"/>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 126 131 126 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B28">28</xref><xref ref-type="bibr" rid="B29"/>&#8211;<xref ref-type="bibr" rid="B30">30</xref></sup>
###xml 279 287 275 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 461 465 457 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AIRE</italic>
###xml 677 685 673 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 687 688 683 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 822 823 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 834 835 830 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 933 937 929 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AIRE</italic>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 584 592 <span type="species:ncbi:9606">patients</span>
###xml 730 738 <span type="species:ncbi:9606">patients</span>
###xml 872 880 <span type="species:ncbi:9606">patients</span>
###xml 1091 1099 <span type="species:ncbi:9606">patients</span>
###xml 1232 1240 <span type="species:ncbi:9606">patients</span>
There are several recent reports of elevated levels of the pro-inflammatory chemokine CXCL10 in endocrine autoimmune diseases.28-30 Our studies here indicate that the neutralizing autoantibodies to IFN-alpha decrease the expression of CXCL10 in blood cells from APECED patients (Figure 2A-C). This prompted us to measure their serum CXCL10 levels; they were assessed by quantitative immunoassay in serum samples available from 49 APECED patients, 39 unaffected AIRE heterozygous relatives, and 9 healthy controls. In contrast with the decreased mRNA levels in blood cells, the APECED patients had significantly higher serum CXCL10 protein levels than the unaffected relatives (Figure 5, P < .001). Levels were even higher than in patients with isolated Addison's disease or autoimmune polyendocrine syndrome type 2 (APS2; P < .01 and P < .05, respectively). In the APECED patients, the CXCL10 levels did not correlate with the exact AIRE mutations, disease-onset ages, or numbers or types of clinical manifestations. Although the values spanned a wide range in each group, nearly all APECED patients were above the medians of the controls or relatives but did vary substantially in serial samples from the same individual Norwegian patients (data not shown).
###end p 43
###begin p 44
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CXCL10 levels in APECED and control sera</bold>
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AIRE</italic>
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
CXCL10 levels in APECED and control sera. CXCL10 levels are significantly higher in APECED than in unaffected AIRE-heterozygous relatives, patients with APS2, Addison disease, or healthy controls. Geometric means of groups are indicated on plots. *P < .05, **P < .01, ***P < .001.
###end p 44
###begin p 45
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 194 195 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
We next investigated serum levels of proinflammatory cytokines in APECED patients and healthy controls. As with CXCL10, we observed a tendency to higher levels of IL-6 (P = .053) and TNF-alpha (P < .05) in APECED than in healthy controls (Table S3). However, the levels of IFN-gamma, IL-10, IL-5, IL-4, and IL-2 showed no significant changes (Table S3 and data not shown).
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 241 242 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 243 244 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 245 246 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 246 246 242 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8"/>
###xml 247 248 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 249 251 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 241 251 237 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref><xref ref-type="bibr" rid="B8"/>&#8211;<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B31">31</xref></sup>
###xml 851 852 832 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 853 855 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 855 855 836 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33"/>
###xml 856 858 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 851 858 832 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B32">32</xref><xref ref-type="bibr" rid="B33"/>&#8211;<xref ref-type="bibr" rid="B34">34</xref></sup>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
###xml 669 673 <span type="species:ncbi:9913">calf</span>
###xml 714 722 <span type="species:ncbi:9606">patients</span>
Our experiments clearly demonstrate down-regulated ISG expression in APECED patients' PBMCs. In sharp contrast, the expression of ISGs is higher in SLE patients, which is consistent with their well-known elevations in serum IFN-alpha levels.2,5,7-9,31 The lower expression of ISGs in APECED patients is apparently caused by neutralizing autoantibodies to the IFN-alpha rather than IFN-beta or IFN-omega. Moreover, anti-IFN-alpha antibody-containing sera clearly down-regulated ISG expression in control monocytes ex vivo and blocked the key IFN-induced early signaling event, STAT1 phosphorylation. Importantly, these effects were reversible; after maturation in fetal calf serum (instead of APECED plasma), these patients' monocyte-derived DCs showed normal expression of ISGs. We propose that deprivation of the normal low levels of circulating IFNs2,32-34 by the neutralizing anti-IFN-alpha antibodies induces a state of type I IFN underactivity that can readily be reversed in culture.
###end p 47
###begin p 48
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 395 397 395 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B35">35</xref></sup>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 509 511 509 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B28">28</xref></sup>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 527 529 527 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B29">29</xref></sup>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 548 550 548 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B36">36</xref></sup>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 570 572 570 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B30">30</xref></sup>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 610 615 610 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref></sup>
###xml 1094 1102 1090 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1140 1142 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 1140 1142 1136 1138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B39">39</xref></sup>
Interestingly, we found markedly elevated levels of the IFN-induced chemokine CXCL10 in APECED sera, averaging approximately 5-fold higher than in healthy controls. In apparent contrast, its mRNA expression was decreased in blood cells. Approximately 5-fold higher serum CXCL10 protein levels have also been described in SLE, with similarly poor correlations with gene expression in blood cells.35 Modest increases in CXCL10 have been described in other organ-specific diseases, such as Hashimoto thyroiditis,28 Graves disease,29 myasthenia gravis,36 and Addison disease30 and also during type I IFN treatment.37,38 In APECED, the autoimmune processes in endocrine tissues are most probably accompanied by IFN-gamma production that is a strong inducer of CXCL10. We propose that chemokines measured in serum are derived not from blood cells but rather from the extravascular target tissues, where they are responding to inflammatory stimuli and thus chemoattracting immune cells out of the circulation. That might explain the slightly decreased percentages of plasmacytoid DCs in APECED blood (Figure 4A), which have also been noted in SLE.39
###end p 48
###begin p 49
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 624 632 <span type="species:ncbi:9606">patients</span>
Type I IFNs are produced in large quantities during many acute viral infections. In physiologic situations, their actions may largely be localized to infected tissues and operate mainly via autocrine and paracrine stimulation. Although the autoantibodies can effectively neutralize IFNs in the bloodstream, they may not reach sufficient levels to do so in the tissues, which might help explain the surprising rarity of viral infections in APECED patients despite their decreased expression of ISGs in blood cells. In addition, there may be compensation by IFN-beta and/or IFN-lambda, which are neutralized much less in most patients.
###end p 49
###begin p 50
###xml 828 830 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 828 830 792 794 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B40">40</xref></sup>
###xml 56 63 <span type="species:ncbi:9606">patient</span>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
###xml 579 586 <span type="species:ncbi:9606">patient</span>
###xml 854 861 <span type="species:ncbi:9606">patient</span>
###xml 955 962 <span type="species:ncbi:9606">patient</span>
###xml 1036 1044 <span type="species:ncbi:9606">patients</span>
###xml 1089 1096 <span type="species:ncbi:9606">patient</span>
The consistently increased expression of ISGs in APECED patient A3, whose neutralizing autoantibodies only recognize IFN-omega (and not IFN-alpha), also hints at an underlying local overproduction of type I IFNs in APECED patients who are masked by the anti-IFN-alpha autoantibodies in the typical cases. Most ISGs are up-regulated by both type I IFNs and IFN-gamma. The normal expression of CIITA, which is selectively up-regulated by IFN-gamma, argues that it does not contribute substantially and thus implicates the IFN-alpha most strongly. The CIITA level was even lower in patient A3, and her serum did contain IFN-alpha because it evoked significant STAT1 phosphorylation in control cells and could be neutralized by anti-IFN-alpha antibodies. Notably, one side effect of treatment with IFN-alpha is thyroid autoimmunity.40 Interestingly, the one patient with detectable serum IFN-alpha and with neutralizing autoantibodies only against IFN-omega (patient A3) also has thyroiditis, which is otherwise rare among Norwegian APECED patients. Similarly, the other serologically similar patient (A2) had thyroid peroxidase autoantibodies.
###end p 50
###begin p 51
###xml 201 203 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 201 203 194 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B41">41</xref></sup>
###xml 302 304 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 302 304 283 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 449 451 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 449 451 426 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B42">42</xref></sup>
###xml 996 998 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 996 998 961 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B43">43</xref></sup>
###xml 1054 1056 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1054 1056 1019 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B10">10</xref></sup>
###xml 1144 1146 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1144 1146 1109 1111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B44">44</xref></sup>
###xml 1247 1249 1212 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 1247 1249 1212 1214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B45">45</xref></sup>
###xml 1291 1293 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 1291 1293 1256 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B46">46</xref></sup>
###xml 1425 1429 1390 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AIRE</italic>
###xml 1601 1603 1566 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 1601 1603 1566 1568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B47">47</xref></sup>
###xml 1800 1808 1765 1773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 786 791 <span type="species:ncbi:9606">human</span>
###xml 1364 1372 <span type="species:ncbi:9606">patients</span>
After virus- or TLR-stimulation, plasmacytoid DCs produce a mixture of type I IFNs, but predominantly IFN-alpha, whereas, after TLR 4 or TLR 3 stimulation, monocyte-derived DCs secrete mainly IFN-beta,41 which is recognized infrequently (approximately 20%) by the neutralizing autoantibodies in APECED.10 Moreover, the type I IFNs show distinct actions; the chemokine-stimulating and DC-maturing properties of IFN-omega seem particularly restricted.42 This is consistent with the observed ISG up-regulation by the APECED sera with neutralizing autoantibodies against only IFN-omega, in contrast to ISG down-regulation by the APECED sera with autoantibodies to IFN-alpha (and IFN-omega). Although our results do not indicate any abnormal IFN overproduction in APECED peripheral DCs, the human thymus contains not only numerous DCs but also many plasmacytoid DCs, which can produce large amounts of type I IFNs. Moreover, they are predominantly located in the medulla and corticomedullary junction,43 where type I IFNs appear to be constitutively secreted.10 Type I IFN overproduction by thymic plasmacytoid DCs impairs thymic T-cell development.44 It is also involved in terminal differentiation and subsequent apoptosis of thymic epithelial cells,45 and so, interestingly, is wild-type AIRE.46 The coincidence of highly prevalent, high-titer IFN autoantibodies in patients with thymic epithelial tumors or genetic defects in AIRE suggests parallel mechanisms of autoimmunization in the APECED thymus and thymomas. Indeed, the neoplastic epithelial cells in thymomas almost always fail to express AIRE.47 We propose that aberrant cell death or some other so far unknown danger signal renders the APECED thymic environment prone to autoimmunize responsive T cells against locally abundant type I IFNs (Figure 6).
###end p 51
###begin p 52
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Schematic illustration of thymic and peripheral events in APECED</bold>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 383 388 <span type="species:ncbi:9606">human</span>
Schematic illustration of thymic and peripheral events in APECED. Tissue-restricted antigen-specific T cells are not deleted in APECED thymus because of the deficient function of AIRE in medullary thymic epithelial cells (mTEC), and escape to cause tissue damage in endocrine organs in APECED patients. We speculate that, because of aberrant cell death or alternative danger signal, human AIRE-deficient thymus (and thymomas) assume some functions of secondary lymphoid organs, with associated overproduction of type I IFNs by thymic DCs. These DCs are activated and present a broad spectrum of type I interferons to autoimmunize specific T and then B cells. The resulting high titer neutralizing antibodies inhibit ISG responses of PBMCs to basal circulating levels of type I IFNs. Autoreactive T cells infiltrating target endocrine tissues secrete IFN-gamma. This induces the production of CXCL10 and further expansion of the adjacent infiltrates.
###end p 52
###begin p 53
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AIRE</italic>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 324 326 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="B46">46</xref></sup>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
In conclusion, we show that ISGs are down-regulated in APECED patients' PBMCs by their autoantibodies against type I IFNs and demonstrate marked increase in serum CXCL10 levels in APECED. Our results suggest that AIRE deficiency causes increased production of IFNs, possibly through aberrant cell death in the APECED thymus,46 which results in highly specific autoantibodies to type I IFNs and down-regulation of ISGs in APECED blood cells.
###end p 53
###begin title 54
Supplementary Material
###end title 54
###begin title 55
[Supplemental Tables]
###end title 55
###begin p 56
The online version of this article contains a data supplement.
###end p 56
###begin p 57
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
###end p 57
###begin title 58
Acknowledgments
###end title 58
###begin p 59
###xml 22 30 <span type="species:ncbi:9606">patients</span>
The authors thank the patients and controls for so kindly providing the generous samples on which this study crucially depends; Dr Kylie E. Webster and Dr Ken Simpson for help in sample preparation and analysis, respectively, of the Affymetrix chips; Ulla Kiiskinen and Elisabeth Halvorsen for technical assistance; and Jim Robertson for influenza virus.
###end p 59
###begin p 60
This work was supported by the Wellcome Trust Senior Fellowship grant, EU Framework program 6 (Thymaide and Euraps; P.P.), the European Regional Fund and Archimedes Foundation, the Estonian Science Foundation (grants 6663, 6514 and 7197; K.K., P.P., M.L.), Slovenian Agency for Research (J3-9663; K.T.P. and T.B.), National Health and Medical Research Council (NHMRC) fellowships (171601 and 461204), and National Health and Medical Research Council (NHMRC) program grants (257501, 264573 and 406700; H.S.S.).
###end p 60
###begin title 61
Authorship
###end title 61
###begin p 62
Contribution: K.K., M.L., A.S.B.W., A. Meager, L.T., A. Murumagi, and H.S.S. performed experiments and analyzed data; K.K. and T.O. performed statistical analysis; A.S.B.W., E.S.H., K.L., K.T.P., T.B., A.L., O.K., A. Meloni, B.E.-L., N.K.M., J.P., K.J.E.K., and R.U. were responsible for collection of clinical material and data; and K.K., N.W., and P.P. designed the research and wrote the paper.
###end p 62
###begin p 63
Conflict-of-interest disclosure: The authors declare no competing financial interests.
###end p 63
###begin p 64
###xml 140 156 140 156 <email xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">kai.kisand@ut.ee</email>
Correspondence: Kai Kisand, Institute of General and Molecular Pathology, University of Tartu, Ravila Str 19, Tartu 50411, Estonia; e-mail: kai.kisand@ut.ee.
###end p 64
###begin title 65
References
###end title 65
###begin article-title 66
Interferons, interferon-like cytokines, and their receptors.
###end article-title 66
###begin article-title 67
Interferons as pathogenic effectors in autoimmunity.
###end article-title 67
###begin article-title 68
###xml 33 38 <span type="species:ncbi:9606">human</span>
###xml 77 89 <span type="species:ncbi:11191">Sendai virus</span>
Monocyte is the main producer of human leukocyte alpha interferons following Sendai virus induction.
###end article-title 68
###begin article-title 69
Liu YJIPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors.
###end article-title 69
###begin article-title 70
###xml 33 38 <span type="species:ncbi:9606">human</span>
Dendritic cells and cytokines in human inflammatory and autoimmune diseases.
###end article-title 70
###begin article-title 71
IRF-7 is the master regulator of type-I interferon-dependent immune responses.
###end article-title 71
###begin article-title 72
An etiopathogenic role for the type I IFN system in SLE.
###end article-title 72
###begin article-title 73
Type I interferon in systemic lupus erythematosus and other autoimmune diseases.
###end article-title 73
###begin article-title 74
Systemic lupus erythematosus: all roads lead to type I interferons.
###end article-title 74
###begin article-title 75
Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.
###end article-title 75
###begin article-title 76
###xml 71 76 <span type="species:ncbi:9606">human</span>
Autoimmune regulator induced changes in the gene expression profile of human monocyte-dendritic cell-lineage.
###end article-title 76
###begin article-title 77
Positional cloning of the APECED gene.
###end article-title 77
###begin article-title 78
Self-representation in the thymus: an extended view.
###end article-title 78
###begin article-title 79
A decade of AIRE.
###end article-title 79
###begin article-title 80
What's new in the Aire?
###end article-title 80
###begin article-title 81
###xml 34 40 <span type="species:ncbi:10090">murine</span>
###xml 111 116 <span type="species:ncbi:10090">mouse</span>
RNA and protein expression of the murine autoimmune regulator gene (Aire) in normal, RelB-deficient and in NOD mouse.
###end article-title 81
###begin article-title 82
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.
###end article-title 82
###begin article-title 83
Autoimmune polyendocrinopathy syndrome type 1 (APS1) and AIRE gene: new views on molecular basis of autoimmunity.
###end article-title 83
###begin article-title 84
###xml 84 92 <span type="species:ncbi:9606">patients</span>
A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1.
###end article-title 84
###begin article-title 85
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Aire deficient mice do not develop the same profile of tissue-specific autoantibodies as APECED patients.
###end article-title 85
###begin article-title 86
###xml 155 163 <span type="species:ncbi:9606">patients</span>
Anticytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis.
###end article-title 86
###begin article-title 87
###xml 42 47 <span type="species:ncbi:9606">human</span>
Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability.
###end article-title 87
###begin article-title 88
Summaries of Affymetrix GeneChip probe level data.
###end article-title 88
###begin article-title 89
Linear models and empirical Bayes methods for assessing differential expression in microarray experiments.
###end article-title 89
###begin article-title 90
Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene.
###end article-title 90
###begin article-title 91
Functional classification of interferon-stimulated genes identified using microarrays.
###end article-title 91
###begin article-title 92
###xml 88 105 <span type="species:ncbi:11103">hepatitis C virus</span>
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.
###end article-title 92
###begin article-title 93
High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism.
###end article-title 93
###begin article-title 94
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.
###end article-title 94
###begin article-title 95
###xml 150 155 <span type="species:ncbi:9606">human</span>
Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines.
###end article-title 95
###begin article-title 96
Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus.
###end article-title 96
###begin article-title 97
A weak signal for strong responses: interferon-alpha/beta revisited.
###end article-title 97
###begin article-title 98
High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus.
###end article-title 98
###begin article-title 99
Interferon messenger RNA is produced constitutively in the organs of normal individuals.
###end article-title 99
###begin article-title 100
###xml 83 88 <span type="species:ncbi:9606">human</span>
Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus.
###end article-title 100
###begin article-title 101
Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis.
###end article-title 101
###begin article-title 102
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis.
###end article-title 102
###begin article-title 103
Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
###end article-title 103
###begin article-title 104
Reduced blood BDCA-2+ (lymphoid) and CD11c+ (myeloid) dendritic cells in systemic lupus erythematosus.
###end article-title 104
###begin article-title 105
Interferon alpha treatment and thyroid dysfunction.
###end article-title 105
###begin article-title 106
###xml 117 122 <span type="species:ncbi:9606">human</span>
Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells.
###end article-title 106
###begin article-title 107
###xml 42 47 <span type="species:ncbi:9606">human</span>
Modification of TLR-induced activation of human dendritic cells by type I IFN: synergistic interaction with TLR4 but not TLR3 agonists.
###end article-title 107
###begin article-title 108
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human thymus contains IFN-alpha-producing CD11c(-), myeloid CD11c(+), and mature interdigitating dendritic cells.
###end article-title 108
###begin article-title 109
###xml 47 52 <span type="species:ncbi:9606">human</span>
Stimulated plasmacytoid dendritic cells impair human T-cell development.
###end article-title 109
###begin article-title 110
###xml 48 53 <span type="species:ncbi:9606">human</span>
Interferons mediate terminal differentiation of human cortical thymic epithelial cells.
###end article-title 110
###begin article-title 111
Proliferative arrest and rapid turnover of thymic epithelial cells expressing Aire.
###end article-title 111
###begin article-title 112
Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1).
###end article-title 112

